Product How it works Pricing Blog FAQ About Contact
Royalty Pharma

Royalty Pharma (NASDAQ: RPRX) net income

Royalty Pharma reported a net profit of $770.9m for fiscal 2025, 10.2% less than in fiscal 2024 ($859.0m). Its net margin was 32.4%. Earnings per share were $1.79.

Royalty Pharma's net income has fallen for 2 years in a row, and its best year of the last 7 was fiscal 2019. The biggest drop was in fiscal 2022, −93.1%.

Net income, in millions of US dollars2,3492019975.02020619.7202142.820221,1352023859.02024770.92025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025$770.9m−10.2%32.4%$1.79
2024$859.0m−24.3%37.9%$1.92
2023$1,135m+2,549.5%48.2%$2.54
2022$42.8m−93.1%1.9%$0.10
2021$619.7m−36.4%27.1%$1.49
2020$975.0m−58.5%45.9%$1.32
2019$2,349m—129.4%—

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Royalty Pharma net income compared with its sector

By net income for its latest fiscal year, Royalty Pharma ranks 50th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Royalty Pharma, 32.4%.

RankCompanyNet incomeNet margin
48thExelixis$782.6m33.7%
49thSteris$782.3m13.2%
50thRoyalty Pharma$770.9m32.4%
51stBIO-RAD Laboratories$759.9m29.4%
52ndDaVita$746.8m5.5%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of Royalty Pharma

How much did Royalty Pharma earn in fiscal 2025?
Royalty Pharma reported a net profit of $770.9m for fiscal 2025. In fiscal 2024 it reported a net profit of $859.0m.
What are the earnings per share of Royalty Pharma?
They were $1.79 in fiscal 2025, compared with $1.92 in fiscal 2024.
What is the net margin of Royalty Pharma?
In fiscal 2025 its net profit was 32.4% of its revenue.
What was the most profitable year for Royalty Pharma?
Of its last 7 fiscal years, fiscal 2019, with $2,349m.
Where does Royalty Pharma rank in its sector by net income?
It ranks 50th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for Royalty Pharma come from?
From the annual report (Form 10-K) that Royalty Pharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Royalty Pharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Royalty Pharma: the Royalty Pharma page · annual accounts · revenue · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.